Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4797623 | 0.92 | CSF1R (0.31) | ALDH2 | |
| SCHEMBL4797241 | 0.85 | DRD2 (0.33) | — | |
| SCHEMBL21722912 | 0.66 | HTR3A (0.42) | ALDH2 | |
| SCHEMBL1200030 | 0.65 | SIGMAR1 (0.45) | — | |
| SCHEMBL21722951 | 0.64 | SLC6A4 (0.42) | — | |
| Hydrochloric Acid SCHEMBL1532735 | 0.64 | SIGMAR1 (0.44) | — | |
| Hydrochloric Acid SCHEMBL31556514 | 0.61 | HTR2C (0.54) | — | |
| SCHEMBL28144221 | 0.61 | CYP2A6 (0.44) | — | |
| Hydrochloric Acid SCHEMBL31556501 | 0.60 | HTR2C (0.55) | — | |
| SCHEMBL22197977 | 0.58 | PTPN11 (0.46) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7332493-B2 | Substituted bicyclic derivatives for the treatment of abnormal cell growth | OSI PHARMACEUTICALS (US) | 2008-02-19 | — | — | US | disclosed |
| US-20050159435-A1 | Substituted bicyclic derivatives for the treatment of abnormal cell growth | PFIZER INC | 2005-07-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050159435-A1 | Substituted bicyclic derivatives for the treatment of abnormal cell growth | CCNA1, CCNT1, CCNB1 | ALDH2 1689/4885P2RY6 3174/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.